ID
13534
Description
Microvascular and Antiinflammatory Effects of Rivaroxaban Compared to Aspirin in Type-2 Diabetic Patients With Cardiovascular Disease; ODM derived from: https://clinicaltrials.gov/show/NCT02164578
Link
https://clinicaltrials.gov/show/NCT02164578
Keywords
Versions (1)
- 2/14/16 2/14/16 -
Uploaded on
February 14, 2016
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility Type 2 Diabetic Patients NCT02164578
Eligibility Type 2 Diabetic Patients NCT02164578
- StudyEvent: Eligibility
Description
Exclusion Criteria
Alias
- UMLS CUI
- C0680251
Description
Cardiovascular event
Data type
boolean
Alias
- UMLS CUI [1]
- C1320716
Description
Uncontrolled hypertension
Data type
boolean
Alias
- UMLS CUI [1]
- C1868885
Description
Hypersensitivity
Data type
boolean
Alias
- UMLS CUI [1]
- C0020517
Description
Bleeding
Data type
boolean
Alias
- UMLS CUI [1]
- C0741554
Description
Bleeding Risk
Data type
boolean
Alias
- UMLS CUI [1]
- C3251812
Description
Antiplatelet therapy
Data type
boolean
Alias
- UMLS CUI [1]
- C1096021
Description
Hepatic disease
Data type
boolean
Description
Chronic renal failure
Data type
boolean
Alias
- UMLS CUI [1]
- C0022661
Description
Pregnant or breast-feeding
Data type
boolean
Alias
- UMLS CUI [1]
- C0549206
- UMLS CUI [2]
- C0006147
Similar models
Eligibility Type 2 Diabetic Patients NCT02164578
- StudyEvent: Eligibility
C0006147 (UMLS CUI [2])
No comments